Flatiron Health today announced eight abstracts were accepted for presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program , to be held May 29–31. “ The research being presented displays the broad impact that real-world data derived from electronic health records has across the oncology therapeutic lifecycle from discovery through development and ultimately in support of patient care,” said Dr. Michael Vasconcelles, chief medical officer at Flatiron. “It is a rich illustration of the knowledge that can be created when experts collaborate across the oncology ecosystem.” The key areas studied include:
- Biomarkers that predict who may benefit from targeted treatments
- Treatment patterns at the end of life
- Barriers and solutions to clinical trial participation
- Novel clinico-genomic research
Flatiron collaborated on the accepted research with: University of Pennsylvania, Yale Cancer Center, Cancer & Hematology Centers of Western Michigan, Florida Cancer Specialists, Hematology Oncology Associates of Central New York, Southeast Nebraska Cancer Center, Tennessee Oncology, West Cancer Center, Foundation Medicine, and Genentech, a member of the Roche Group. Full abstracts will be posted at rwe.flatiron.com post-ASCO embargo on May 29.
Poster Presentations
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous NSCLC
First Author: Deborah B. Doroshow, Icahn School of Medicine at Mount Sinai
Abstract: 9539
Poster: 305
Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate resistant prostate cancer (mCRPC)
First Author: Emmanuel S. Antonarakis, Sidney Kimmel Comprehensive Cancer Center
Abstract: 5527
Poster: 108
Use of real world data to understand barriers to interventional clinical trial enrollment in community oncology clinics (COC)
First Author: Johnetta Blakely, Tennessee Oncology
Abstract: 2061
Poster: 5
The adoption of immune checkpoint inhibitors and patterns of care at the end of life
First Author: Fauzia Riaz, Yale School of Medicine
Abstract: 12027
Poster: 315
A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic; imaging; and outcomes data for patients with metastatic lung cancer
First Author: Michael W. Lu, Genentech
Abstract: TPS2087
Poster: 79
An automated EHR-based tool for identification of patients (pts) with metastatic disease to facilitate clinical trial patient ascertainment
First Author: Jeffrey J. Kirshner, Hematology Oncology Associates of Central New York
Abstract: 2051
Poster: 43
Characteristics and outcomes of real-world patients with microsatellite instability-high (MSI-H) solid tumors treated with pembrolizumab monotherapy after FDA approval
First Author: Tamara Snow, Flatiron Health
Abstract: 3060
Poster: 124
Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size
First Author: Sai-Hong I. Ou, University of California Irvine Chao Comprehensive Cancer Center
Abstract: 9591
Poster: 357
Location:
NEW YORK, NY, May 14, 2020
About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
